{"id":40312,"date":"2001-04-01T12:06:00","date_gmt":"2001-04-01T10:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin"},"modified":"2001-04-01T12:06:00","modified_gmt":"2001-04-01T10:06:00","slug":"nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\/","title":{"rendered":"Nochmals: Hyperkinetisches Syndrom und Methylphenidat (Ritalin)"},"content":{"rendered":"<p>Zur Erg\u00e4nzung unseres Referats zur Therapie des Hyperkinetischen Syndroms mit Methylphenidat (AMB 2001, 35, 12) hat uns ein Leser auf eine aktuelle, alarmierende Arbeit aus G\u00f6ttingen hingewiesen (Moll, G.H., et al.: J. Child Adolesc. Psych. Pharmacol. 2001, 11, 15). In einem Tierexperiment wurde sehr jungen und postpubert\u00e4ren Ratten zwei Wochen lang Methylphenidat verabreicht. Es konnte [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zur Erg\u00e4nzung unseres Referats zur Therapie des Hyperkinetischen Syndroms mit Methylphenidat (AMB 2001, 35, 12) hat uns ein Leser auf eine aktuelle, alarmierende Arbeit aus G\u00f6ttingen hingewiesen (Moll, G.H., et al.: J. Child Adolesc. Psych. Pharmacol. 2001, 11, 15). In einem Tierexperiment wurde sehr jungen und postpubert\u00e4ren Ratten zwei Wochen lang Methylphenidat verabreicht. Es konnte [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[2999,4180,3000,5276,1274,5864,7130],"class_list":["post-40312","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-adhs","tag-attention-deficit-hyperactivity-disorder","tag-aufmerksamkeitsdefizit-hyperaktivitaetssyndrom","tag-hyperkinetisches-syndrom","tag-methylphenidat","tag-mta-studie","tag-zappelphilipp-syndrom"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nochmals: Hyperkinetisches Syndrom und Methylphenidat (Ritalin) - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nochmals: Hyperkinetisches Syndrom und Methylphenidat (Ritalin) - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"Zur Erg\u00e4nzung unseres Referats zur Therapie des Hyperkinetischen Syndroms mit Methylphenidat (AMB 2001, 35, 12) hat uns ein Leser auf eine aktuelle, alarmierende Arbeit aus G\u00f6ttingen hingewiesen (Moll, G.H., et al.: J. Child Adolesc. Psych. Pharmacol. 2001, 11, 15). In einem Tierexperiment wurde sehr jungen und postpubert\u00e4ren Ratten zwei Wochen lang Methylphenidat verabreicht. Es konnte [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2001-04-01T10:06:00+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg\" \/>\n<meta name=\"author\" content=\"Dennis Hoppe\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Hoppe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\\\/\"},\"author\":{\"name\":\"Dennis Hoppe\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"headline\":\"Nochmals: Hyperkinetisches Syndrom und Methylphenidat (Ritalin)\",\"datePublished\":\"2001-04-01T10:06:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\\\/\"},\"wordCount\":220,\"keywords\":[\"ADHS\",\"Attention deficit\\\/Hyperactivity disorder\",\"Aufmerksamkeitsdefizit-Hyperaktivit\u00e4tssyndrom\",\"Hyperkinetisches Syndrom\",\"Methylphenidat\",\"MTA-Studie\",\"Zappelphilipp-Syndrom\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\\\/\",\"name\":\"Nochmals: Hyperkinetisches Syndrom und Methylphenidat (Ritalin) - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"datePublished\":\"2001-04-01T10:06:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nochmals: Hyperkinetisches Syndrom und Methylphenidat (Ritalin)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\",\"name\":\"Dennis Hoppe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"caption\":\"Dennis Hoppe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nochmals: Hyperkinetisches Syndrom und Methylphenidat (Ritalin) - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\/","og_locale":"de_DE","og_type":"article","og_title":"Nochmals: Hyperkinetisches Syndrom und Methylphenidat (Ritalin) - Der Arzneimittelbrief","og_description":"Zur Erg\u00e4nzung unseres Referats zur Therapie des Hyperkinetischen Syndroms mit Methylphenidat (AMB 2001, 35, 12) hat uns ein Leser auf eine aktuelle, alarmierende Arbeit aus G\u00f6ttingen hingewiesen (Moll, G.H., et al.: J. Child Adolesc. Psych. Pharmacol. 2001, 11, 15). In einem Tierexperiment wurde sehr jungen und postpubert\u00e4ren Ratten zwei Wochen lang Methylphenidat verabreicht. Es konnte [&hellip;]","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2001-04-01T10:06:00+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg","type":"","width":"","height":""}],"author":"Dennis Hoppe","twitter_misc":{"Verfasst von":"Dennis Hoppe","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\/"},"author":{"name":"Dennis Hoppe","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"headline":"Nochmals: Hyperkinetisches Syndrom und Methylphenidat (Ritalin)","datePublished":"2001-04-01T10:06:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\/"},"wordCount":220,"keywords":["ADHS","Attention deficit\/Hyperactivity disorder","Aufmerksamkeitsdefizit-Hyperaktivit\u00e4tssyndrom","Hyperkinetisches Syndrom","Methylphenidat","MTA-Studie","Zappelphilipp-Syndrom"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\/","name":"Nochmals: Hyperkinetisches Syndrom und Methylphenidat (Ritalin) - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"datePublished":"2001-04-01T10:06:00+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Nochmals: Hyperkinetisches Syndrom und Methylphenidat (Ritalin)"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16","name":"Dennis Hoppe","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","caption":"Dennis Hoppe"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=40312"}],"version-history":[{"count":0,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40312\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=40312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=40312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=40312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}